Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study

Elena P Calandre, Piedad Morillas-Arques, Rocío Molina-Barea, Carmen M Rodriguez-Lopez, Fernando Rico-Villademoros, Elena P Calandre, Piedad Morillas-Arques, Rocío Molina-Barea, Carmen M Rodriguez-Lopez, Fernando Rico-Villademoros

Abstract

Background: Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied. If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone. The aim of the present study was to assess the effectiveness of trazodone alone and in combination with pregabalin in the treatment of fibromyalgia.

Methods: This was an open-label uncontrolled study. Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period. Outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburgh Sleep Quality Index (PSQI), the Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Scale (HADS), the Brief Pain Inventory (BPI), the Short-Form Health Survey (SF-36), and the Patients' Global Improvement scale (PGI). Emergent adverse reactions were recorded. Data were analyzed with repeated measures one-way ANOVA and paired Student's t test.

Results: Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain. After pregabalin combination additional and significant improvements were seen on fibromyalgia severity, depression and pain interference with daily activities, and a decrease in bodily pain was also apparent. During the second phase of the study, only two patients dropped out due to side effects.

Conclusions: Trazodone significantly improved fibromyalgia severity and associated symptomatology. Its combination with pregabalin potentiated this improvement and the tolerability of the drugs in association was good.

Trial registration: ClinicalTrials.gov: NCT00791739.

Figures

Figure 1
Figure 1
Patients flow diagram.
Figure 2
Figure 2
Responder analysis of pain improvement in BPI severity scores.
Figure 3
Figure 3
Patients' Global Improvement scale at weeks 12 and 24.
Figure 4
Figure 4
Emergent adverse drug reactions during the study period.

References

    1. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. OMERACT Fibromyalgia Working Group. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36:2318–2329. doi: 10.3899/jrheum.090367.
    1. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;46:469–476.
    1. Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Artzeni F. Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum. 2008;37:353–365. doi: 10.1016/j.semarthrit.2007.08.008.
    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27. doi: 10.1186/1471-2474-8-27.
    1. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums. 2009;14:536–546.
    1. Branco JC, Martini A, Paiva T. Treatment of sleep abnormalities and clinical complaints in fibromyalgia with trazodone. Arthritis Rheum. 1996;39:S91.
    1. Clayton AH, West SG. Combination therapy for fibromyalgia. Curr Pharm Design. 2006;12:11–16.
    1. Mease PJ, Seymour K. Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy? Curr Pain Headache Rep. 2008;12:399–405. doi: 10.1007/s11916-008-0068-4.
    1. Hughes G, Martinez C, Myon E, Taïeb C, Wessely S. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum. 2006;54:177–183. doi: 10.1002/art.21545.
    1. Wolfe F, Claw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–610. doi: 10.1002/acr.20140.
    1. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40:1560–1570. doi: 10.1002/art.1780400904.
    1. White KP, Nielson WR, Harth M, Ostbye T, Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002;47:260–265. doi: 10.1002/art.10400.
    1. Boomershine CS. Pregabalin for the management of fibromyalgia syndrome. J Pain Res. 2010;3:81–88.
    1. Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, Rico-Villademoros F, Calandre EP. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:204. doi: 10.1186/1471-2474-11-204.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardieri C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160–172. doi: 10.1002/art.1780330203.
    1. Rivera J, González T. The Fibromyalgia Impact Questionnaire: A validated spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004;22:554–460.
    1. Royuela A, Macías JA. Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño. 1997;9:81–94.
    1. Vazquez C, Sanz J. Fiabilidad y valores normales de la versión española del inventario para la depresión de Beck de 1978. Clin Salud. 1997;8:403–422.
    1. Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I. Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 2003;107:216–221. doi: 10.1034/j.1600-0447.2003.00062.x.
    1. Badia X, Muriel C, Gracia A, Núñez-Olarte JM, Perulero N, Galvez R, Carulla J, Cleeland CS, Grupo Vesbpi. Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc) 2003;120:52–59. doi: 10.1157/13042265.
    1. Alonso J, Prieto L, Antó JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 1995;104:771–776.
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki RA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121. doi: 10.1016/j.jpain.2007.09.005.
    1. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U. Pregabalin 1008-105 Study group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273. doi: 10.1002/art.20983.
    1. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514.
    1. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyiline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheumn. 1986;29:1371–1377. doi: 10.1002/art.1780291110.
    1. Fossaluza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharm Res. 1992;12:99–102.
    1. Cantini F, Bellandi F, Niccoli L, Di Munno O. Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia. Minerva Med. 1994;85:97–100.
    1. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852–1859. doi: 10.1002/art.1780391111.
    1. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, Rico-Villademoros F, Hidalgo J. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label prospective study. Pharmacopsychiatry. 2007;40:58–71. doi: 10.1055/s-2007-970143.
    1. Kim SH, Song J, Mun H, Park KU. Effect of the combined use of tramadol and milnacipran on pain threshold on an animal model of fibromyalgia. Korean J Intern Med. 2009;24:139–142. doi: 10.3904/kjim.2009.24.2.139.
    1. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21:180–191. doi: 10.1007/BF02908299.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj